世界の遺伝子治療市場2021-2028:疾患別(大細胞型B細胞リンパ腫、ベータサラセミアメジャー/SCD)、ベクタータイプ別(レンチウイルス、AAV)、地域別

◆英語タイトル:Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Large B-cell Lymphoma, Beta-Thalassemia Major/SCD), By Vector Type (Lentivirus, AAV), By Region, And Segment Forecasts, 2021 - 2028
◆商品コード:GV21MC019
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2021年2月26日
◆ページ数:180
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥678,300見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥792,300見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,020,300見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

グランドビューリサーチ社は、世界の遺伝子治療市場規模が年平均20.4%成長し、2028年までに100億ドルに達すると予測しています。本調査レポートでは、遺伝子治療の世界市場について調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、疾患別(急性リンパ芽球性白血病(ALL)、遺伝性網膜疾患、大細胞型B細胞リンパ腫、アデノシンデアミナーゼ(ADA)欠損型重症複合免疫不全症(SCID)、黒色腫(病変))分析、ベクタータイプ別(レンチウイルス、AAV、レトロウイルス&ガンマレトロウイルス、変異型単純ヘルペスウイルス、アデノウイルス)分析、地域別分析、企業情報などを掲載しています。
・エグゼクティブサマリー
・調査手法
・市場変動・動向・範囲
・遺伝子治療の世界市場規模:疾患別(急性リンパ芽球性白血病(ALL)、遺伝性網膜疾患、大細胞型B細胞リンパ腫、アデノシンデアミナーゼ(ADA)欠損型重症複合免疫不全症(SCID)、黒色腫(病変))
・遺伝子治療の世界市場規模:ベクタータイプ別(レンチウイルス、AAV、レトロウイルス&ガンマレトロウイルス、変異型単純ヘルペスウイルス、アデノウイルス)
・遺伝子治療の世界市場規模:地域別
・企業情報
【レポートの概要】

Gene Therapy Market Growth & Trends

The global gene therapy market size is expected to reach USD 10.0 billion by 2028 registering a CAGR of 20.4% during the forecast period, according to a new report by Grand View Research, Inc. The market growth is attributed to the increasing prevalence of cancer coupled with the lack of effective treatment for the disease. Constant expansion of cancer genetic studies has deciphered relevant information about cancer-related molecular signatures.

This has driven the clinical trials for advanced cancer therapeutics, thereby driving the market growth. In addition, expansion of this mode of treatment in non-cancer applications with approval of therapies, such as approval of Bluebird Bio’s Zynteglo in June 2019 for β-thalassemia and others, demonstrates the shift in the preferences of companies towards other unsaturated segments.

Various universities and institutes are observed to exhibit a broad portfolio in the pipeline, which is anticipated to boost revenue generation in the future. The market is anticipated to witnesses a short-term revenue slowdown due to a shift in focus and delay in product launches. However, initiatives for developing novel trial designs, improving the regulatory environment, and managing the supply chain are expected to play a critical role in minimizing the impact of the current global crisis.

Gene Therapy Market Report Highlights

• Viral vectors have proven their efficiency as a method for effective gene deliveries. As a result, a substantial number of research communities and biotechnology companies have designed their gene therapy programs based on viral vectors

• Moreover, most of currently FDA-secured products involve the use of viral vectors, which contributes to the dominance of the viral vectors segment

• Due to the approval and huge success of lentivirus-based Kymriah and retrovirus-based Yescarta, retrovirus and lentivirus are also among the key revenue-generating segments

• Cancer has led the revenue flow in the market over the past few years and is expected to maintain its dominance in the forecast period

• The presence of approved products for various cancer forms including Large B-cell lymphoma, Acute Lymphoblastic Leukemia (ALL), and melanoma has resulted in the dominance of this segment

• The U.S. is recognized as the hub for clinical trials related to gene therapy. This has significantly impacted the revenue growth of the North America market

• Also, the success of Yescarta and Kymriah in the U.S. as the first approved CAR-t therapy programs has driven huge investments by various government agencies, sponsors, and key companies in this region

• Major market participants are partnering with other key stakeholders via signing licensing, commercialization, and development deals to enhance their worldwide business operations

• For instance, in June 2020, uniQure announced a license agreement with CSL Behring for the commercialization of hemophilia B gene therapy

【レポートの目次】

Table of Contents

Chapter 1 Gene Therapy Makret: Executive Summary
1.1 Market Summary
Chapter 2 Gene Therapy Makret: Research Methodology
2.1 Information Procurement
2.2 Information Or Data Analysis
2.3 Market Model
2.3.1 Historic And Base Year Estimates
2.3.2 Forecast Analysis
2.3.3 Study Of Approved Therapies By Disease Incidence
2.3.4 Study Of Approved Therapies By Vector
2.3.5 Region-Wise Approval
Chapter 3 Gene Therapy Makret: Market Variables, Trends, & Scope
3.1 Market Trends & Outlook
3.2 Market Segmentation
3.3 Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 Robust gene therapy pipeline
3.3.1.2 Introduction of technological advancements
3.3.1.3 Increasing investment from the companies and partnerships
3.3.1.4 Growing prevalence of target diseases and increased demand for innovative medicine
3.3.2 Market restraint analysis
3.3.2.1 Absence of effective Diagnosis Framework
3.3.2.2 High prices of gene therapy
3.3.3 Market opportunity analysis
3.3.3.1 Rising investment for adoptive T cell transfer approaches of disease treatment
3.3.3.2 Facility expansion for cell and gene therapies
3.3.3.3 Technological advancements in manufacturing vectors
3.3.4 Market challenge analysis
3.3.4.1 Production capacity challenges
3.3.4.2 Manufacturing challenges pertaining to large-scale production of vectors
3.4 Regulatory Framework
3.5 Major Deals & Strategic Alliances Analysis
3.5.1 Mergers & acquisitions
3.5.2 Collaborations & partnerships
3.6 Pipeline Analysis
3.7 Payment & Pricing Models
3.7.1 Payment models for innovative therapies
3.8 SWOT analysis, by factor (Political & legal, economic, and technological)
3.9 Porter’s Five Forces Analysis
3.10 COVID-19 Impact Analysis
3.10.1 Key Market Initiatives
3.10.2 Conclusion
Chapter 4 Gene Therapy Makret: Indication Business Analysis
4.1 Gene therapy market: Indication Movement Analysis
4.2 Acute Lymphoblastic Leukemia (ALL)
4.2.1 Global gene therapy market for Acute Lymphoblastic Leukemia (ALL), 2017 – 2028 (USD Million)
4.3 Inherited Retinal Disease
4.3.1 Global gene therapy market for inherited retinal disease, 2017 – 2028 (USD Million)
4.4 Large B-cell Lymphoma
4.4.1 Global gene therapy market for large B-cell lymphoma, 2017 – 2028 (USD Million)
4.5 Adenosine Deaminase (ADA)‐Deficient Severe Combined Immunodeficiency (SCID)
4.5.1 Global gene therapy market for ADA-SCID, 2017 – 2028 (USD Million)
4.6 Melanoma (Lesions)
4.6.1 Global gene therapy market for melanoma (lesions), 2017 – 2028 (USD Million)
4.7 Beta-Thalassemia Major/Sickle Cell Disease (SCD)
4.7.1 Global gene therapy market for Beta-Thalassemia Major/SCD, 2017 – 2028 (USD Million)
4.8 Head & Neck Squamous Cell Carcinoma
4.8.1 Global gene therapy market for head & neck squamous cell carcinoma, 2017 – 2028 (USD Million)
4.9 Peripheral Arterial Disease
4.9.1 Global gene therapy market for peripheral arterial disease, 2017 – 2028 (USD Million)
4.10 Spinal Muscular Atrophy (SMA)
4.10.1 Global gene therapy market for Spinal Muscular Atrophy (SMA), 2017 – 2028 (USD Million)
4.11 Others
4.11.1 Global gene therapy market for Others, 2017 – 2028 (USD Million)
Chapter 5 Gene Therapy Makret: Vector Type Business Analysis
5.1 Gene Therapy Market: Vector Type Movement Analysis
5.2 Gene Therapy Market: Technology Movement Analysis
5.3 Lentiviral Vectors
5.3.1 Global lentivirus-based gene therapy market, 2017 – 2028 (USD Million)
5.4 Adeno-Associated Viral (AAV) Vectors
5.4.1 Global AAV-based gene therapy market, 2017 – 2028 (USD Million)
5.5 RetroVirus & gamma RetroVirus Vectors
5.5.1 Global RetroVirus & gamma RetroVirus vectors-based gene therapy market, 2017 – 2028 (USD Million)
5.6 Modified Herpes Simplex Virus
5.6.1 Global modified herpes simplex virus vectors-based gene therapy market, 2017 – 2028 (USD Million)
5.7 Adenovirus Vectors
5.7.1 Global adenovirus vectors -based gene therapy market, 2017 – 2028 (USD Million)
5.8 Non-viral Plasmid
5.8.1 Global Non-viral plasmid-based gene therapy market, 2017 – 2028 (USD Million)
Chapter 6 Gene Therapy Makret: Regional Business Analysis
6.1 Gene Therapy Market Share, By Region
6.2 Gene Therapy Market: Regional Movement Analysis
6.3 North America
6.3.1 North America Gene therapy market estimates and forecast, 2017 – 2028 (USD Million)
6.3.2 The U.S.
6.3.2.1 The U.S. gene therapy market, by indication, 2017 – 2028 (USD Million)
6.3.2.2 The U.S. gene therapy market, by vector type, 2017 – 2028 (USD Million)
6.3.3 Canada
6.3.3.1 Canada gene therapy market, by indication, 2017 – 2028 (USD Million)
6.3.3.2 Canada gene therapy market, by vector type, 2017 – 2028 (USD Million)
6.4 Europe
6.4.1 Europe gene therapy market estimates and forecast, 2017 – 2028 (USD Million)
6.5 Asia Pacific
6.5.1 Asia Pacific gene therapy market estimates and forecast, 2017 – 2028 (USD Million)
6.5.2 Japan
6.5.2.1 Japan gene therapy market, by indication, 2017 – 2028 (USD Million)
6.5.2.2 Japan gene therapy market, by vector type, 2017 – 2028 (USD Million)
6.5.3 China
6.5.2.1 China gene therapy market, by indication, 2017 – 2028 (USD Million)
6.5.2.2 China gene therapy market, by vector type, 2017 – 2028 (USD Million)
6.5.4 Russia
6.5.4.1 Russia gene therapy market, by indication, 2017 – 2028 (USD Million)
6.5.4.2 Russia gene therapy market, by vector type, 2017 – 2028 (USD Million)
6.5.5 Australia
6.5.5.1 Australia gene therapy market, by indication, 2017 – 2028 (USD Million)
6.5.5.2 Australia gene therapy market, by vector type, 2017 – 2028 (USD Million)
6.6 RoW
6.6.1 RoW gene therapy market estimates and forecast, 2017 – 2028 (USD Million)
Chapter 7 GENE THERAPY MAKRET: COMPANY Profiles
7.1 Company Profiles
7.1.1 REGENXBIO, Inc.
7.1.1.1 Company overview
7.1.1.2 Financial performance
7.1.1.3 Product benchmarking
7.1.1.4 Strategic Initiatives
7.1.2 Oxford BioMedica plc
7.1.2.1 Company overview
7.1.2.2 Financial performance
7.1.2.3 Product benchmarking
7.1.2.4 Strategic Initiatives
7.1.3 Voyager Therapeutics
7.1.3.1 Company overview
7.1.3.2 Financial performance
7.1.3.3 Product benchmarking
7.1.3.4 Strategic Initiatives
7.1.4 Human Stem Cells Institute
7.1.4.1 Company overview
7.1.4.2 Financial performance
7.1.4.3 Product benchmarking
7.1.4.4 Strategic Initiatives
7.1.5 Dimension Therapeutics, Inc.
7.1.5.1 Company overview
7.1.5.1.1 Financial performance
7.1.5.2 Product benchmarking
7.1.5.3 Strategic Initiatives
7.1.6 Bristol-Myers Squibb Company
7.1.6.1 Company overview
7.1.6.1.1 Celgene Corporation
7.1.6.2 Financial performance (Bristol-Myers Squibb)
7.1.6.2.1 Financial performance (Celgene Corporation)
7.1.6.3 Product benchmarking (Bristol-Myers Squibb)
7.1.6.3.1 Product benchmarking (Celgene)
7.1.6.4 Strategic Initiatives
7.1.7 Sanofi
7.1.7.1 Company overview
7.1.7.2 Financial performance
7.1.7.3 Product benchmarking
7.1.7.4 Strategic Initiatives
7.1.8 Applied Genetic Technologies Corporation
7.1.8.1 Company overview
7.1.8.2 Financial performance
7.1.8.3 Product benchmarking
7.1.8.4 Strategic Initiatives
7.1.9 F. Hoffmann-La Roche Ltd.
7.1.9.1 Company overview
7.1.9.1.1 Spark Therapeutics, Inc.
7.1.9.2 Financial performance
7.1.9.2.1 Financial performance
7.1.9.3 Product benchmarking
7.1.9.4 Strategic Initiatives
7.1.10 bluebird Bio, Inc.
7.1.10.1 Company overview
7.1.10.2 Financial performance
7.1.10.3 Product benchmarking
7.1.10.4 Strategic Initiatives
7.1.11 Novartis AG
7.1.11.1 Company overview
7.1.11.1.1 AveXis, Inc.
7.1.11.2 Financial performance
7.1.11.2.1 Financial performance (AveXis)
7.1.11.3 Product benchmarking
7.1.11.4 Strategic Initiatives
7.1.11.4.1 Strategic Initiatives
7.1.12 Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
7.1.12.1 Company overview
7.1.12.2 Financial performance
7.1.12.3 Product benchmarking
7.1.12.4 Strategic Initiatives
7.1.13 UniQure N.V.
7.1.13.1 Company overview
7.1.13.2 Financial performance
7.1.13.3 Product benchmarking
7.1.13.4 Strategic Initiatives
7.1.14 Shire Plc
7.1.14.1 Company overview
7.1.14.2 Financial performance
7.1.14.3 Product benchmarking
7.1.14.4 Strategic Initiatives
7.1.15 Cellectis S.A.
7.1.15.1 Company overview
7.1.15.2 Financial performance
7.1.15.3 Product benchmarking
7.1.15.4 Strategic Initiatives
7.1.16 Sangamo Therapeutics, Inc.
7.1.16.1 Company overview
7.1.16.2 Financial performance
7.1.16.3 Product benchmarking
7.1.16.4 Strategic Initiatives
7.1.17 Orchard Therapeutics
7.1.17.1 Company overview
7.1.17.2 Financial performance
7.1.17.3 Product benchmarking
7.1.17.4 Strategic Initiatives
7.1.18 Gilead Lifesciences, Inc.
7.1.18.1 Company overview
7.1.18.2 Financial Performance
7.1.18.3 Product benchmarking
7.1.18.4 Strategic Initiatives
7.1.19 BENITEC BIOPHARMA
7.1.19.1 Company overview
7.1.19.2 Financial Performance
7.1.19.3 Product benchmarking
7.1.19.4 Strategic Initiatives
7.1.20 Sibiono GeneTech Co., Ltd
7.1.20.1 Company overview
7.1.20.2 Product benchmarking
7.1.21 Shanghai Sunway Biotech Co., Ltd.
7.1.21.1 Company overview
7.1.21.2 Product benchmarking
7.1.22 Gensight Biologics S.A.
7.1.22.1 Company overview
7.1.22.2 Financial performance
7.1.22.3 Product benchmarking
7.1.22.4 Strategic initiatives
7.1.23 Transgene
7.1.23.1 Company overview
7.1.23.2 Financial performance
7.1.23.3 Product benchmarking
7.1.23.4 Strategic initiatives
7.1.24 Calimmune, Inc.
7.1.24.1 Company overview
7.1.24.2 Product benchmarking
7.1.24.3 Strategic initiatives
7.1.25 Epeius Biotechnologies Corp.
7.1.25.1 Company overview
7.1.25.2 Financial performance
7.1.25.3 Product benchmarking
7.1.26 Astellas Pharma Inc.
7.1.26.1 Company overview
7.1.26.2 Audentes Therapeutics, Inc.
7.1.26.2.1 Company overview
7.1.26.3 Financial performance
7.1.26.3.1 Financial performance
7.1.26.4 Product benchmarking
7.1.26.5 Strategic initiatives
7.1.27 American Gene Technologies
7.1.27.1 Company overview
7.1.27.2 Product benchmarking
7.1.27.3 Strategic initiatives
7.1.28 BioMarin Pharmaceuticals, Inc.
7.1.28.1 Company overview
7.1.28.2 Financial performance
7.1.28.3 Product benchmarking
7.1.28.4 Strategic initiatives

List of Tables

TABLE 1 Ongoing projects for CAR T-cell therapies
TABLE 2 Non-viral DNA vectors (non-replicating) in gene therapy trials
TABLE 3 Some of the examples of molecules under development based on lentiviral vectors
TABLE 4 Molecules in development based on AAV vectors
TABLE 5 North America gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 6 North America gene therapy market, by vector type, 2017 - 2028 (USD Million)
TABLE 7 The U.S. gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 8 The U.S. gene therapy market, by vector type, 2017 - 2028 (USD Million)
TABLE 9 Canada gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 10 Canada gene therapy market, by vector type, 2017 - 2028 (USD Million)
TABLE 11 Europe gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 12 Europe gene therapy market, by vector type, 2017 - 2028 (USD Million)
TABLE 13 Asia Pacific gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 14 Asia Pacific gene therapy market, by vector type, 2017 - 2028 (USD Million)
TABLE 15 China gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 16 China gene therapy market, by vector type, 2017 - 2028 (USD Million)
TABLE 17 Japan gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 18 Japan gene therapy market, by vector type, 2017 - 2028 (USD Million)
TABLE 19 Russia gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 20 Russia gene therapy market, by vector type, 2017 - 2028 (USD Million)
TABLE 21 Australia gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 22 Australia gene therapy market, by vector type, 2017 - 2028 (USD Million)
TABLE 23 RoW gene therapy market, by indication type, 2017 - 2028 (USD Million)
TABLE 24 RoW gene therapy market, by vector type, 2017 - 2028 (USD Million)

List of Figures

FIG. 1 Market summary (USD Million)
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value chain based sizing & forecasting
FIG. 7 QFD modelling for market share assessment
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Global gene therapy pipeline as of 2017, by phase of trial
FIG. 12 Global cancer incidence, as of 2019/2020
FIG. 13 Market restraint relevance analysis (Current & future impact)
FIG. 14 Gene therapy prices by eligible patients per year
FIG. 15 Annual Investment in the CAR-T Space, 2013-2026
FIG. 16 Global financings in cell therapy, 2017-2019
FIG. 17 Recent and ongoing manufacturing capacity expansions for viral vector and large-scale cell therapies, as of 2017
FIG. 18 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 19 Porter’s Five Forces Analysis
FIG. 20 Gene therapy market: Indication type outlook key takeaways
FIG. 21 Gene therapy market: Indication type movement analysis
FIG. 22 Global gene therapy market for Acute Lymphoblastic Leukemia (ALL), 2017 - 2028 (USD Million)
FIG. 23 Global gene therapy market for inherited retinal disease, 2017 - 2028 (USD Million)
FIG. 24 Global gene therapy market for large B-cell lymphoma, 2017 - 2028 (USD Million)
FIG. 25 Global gene therapy market for ADA-SCID, 2017 - 2028 (USD Million)
FIG. 26 Global gene therapy market for melanoma (lesions), 2017 - 2028 (USD Million)
FIG. 27 Global gene therapy market for Beta-Thalassemia Major/SCD, 2017 - 2028 (USD Million)
FIG. 28 Global gene therapy market for head & neck squamous cell carcinoma, 2017 - 2028 (USD Million)
FIG. 29 Global gene therapy market for peripheral arterial disease, 2017 - 2028 (USD Million)
FIG. 30 Global gene therapy market for Spinal Muscular Atrophy (SMA), 2017 - 2028 (USD Million)
FIG. 31 Global gene therapy market for other indications, 2017 - 2028 (USD Million)
FIG. 32 Gene therapy market vector type outlook: Key takeaways
FIG. 33 Gene therapy market: Vector type movement analysis
FIG. 34 Global lentivirus-based gene therapy market, 2017 - 2028 (USD Million)
FIG. 35 Global AAV-based gene therapy market, 2017 - 2028 (USD Million)
FIG. 36 Global retrovirus vectors-based gene therapy market, 2017 - 2028 (USD Million)
FIG. 37 Global modified herpes simplex virus vectors -based gene therapy market, 2017 - 2028 (USD Million)
FIG. 38 Global adenovirus vectors -based gene therapy market, 2017 - 2028 (USD Million)
FIG. 39 Global plasmids-based gene therapy market, 2017 - 2028 (USD Million)
FIG. 40 Regional market place: Key takeaway
FIG. 41 Gene therapy regional outlook, 2020 & 2028
FIG. 42 North America gene therapy market, 2017 - 2028 (USD Million)
FIG. 43 The U.S. gene therapy market, 2017 - 2028 (USD Million)
FIG. 44 Canada gene therapy market, 2017 - 2028 (USD Million)
FIG. 45 Europe gene therapy market, 2017 - 2028 (USD Million)
FIG. 46 Asia Pacific gene therapy market, 2017 - 2028 (USD Million)
FIG. 47 China gene therapy market, 2017 - 2028 (USD Million)
FIG. 48 Japan gene therapy market, 2017 - 2028 (USD Million)
FIG. 49 Russia gene therapy market, 2017 - 2028 (USD Million)
FIG. 50 Australia gene therapy market, 2017 - 2028 (USD Million)
FIG. 51 RoW gene therapy market, 2017 - 2028 (USD Million)
FIG. 52 Strategy framework

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の遺伝子治療市場2021-2028:疾患別(大細胞型B細胞リンパ腫、ベータサラセミアメジャー/SCD)、ベクタータイプ別(レンチウイルス、AAV)、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆